Galera Therapeutics Announces Merger With Obsidian; $350M PIPE Closed

What Happened

• Galera Therapeutics, Inc. announced it entered into a definitive Merger Agreement with Obsidian Therapeutics and related Gazelle Parent entities under which Galera and Obsidian will each become wholly owned subsidiaries of Parent upon closing. The Merger structure uses Gazelle Merger Subsidiary as Galera Merger Sub and Onyx MergerSub for Obsidian.
• Concurrently, Galera completed a private PIPE financing on July 31, 2026, selling Series C Non‑Voting Convertible Preferred Stock for approximately $350.0 million in aggregate gross proceeds. The units were issued in private placements exempt from registration under Section 4(a)(2) of the Securities Act.
• Galera declared a Pre‑Closing Distribution of contingent value rights (CVRs) to holders of Galera common stock (record date July 31, 2026). The distribution date is expected to be August 6, 2026 (three business days after the expected Galera Effective Time).

Key Details

• Parties: Galera, Obsidian, Gazelle Parent, Onyx MergerSub (for Obsidian) and Gazelle Merger Subsidiary (for Galera).
• PIPE: Series C Non‑Voting Convertible Preferred Stock; closed July 31, 2026; aggregate gross proceeds ≈ $350.0 million; issuance exempt under Section 4(a)(2).
• CVRs: Each share of Galera common stock will receive two CVRs — one tied to proceeds from disposition/licensing of tilarganine and one tied to proceeds from disposition/licensing of GC4711 (rucosopasem) and GC4419 (avasopasem). CVR payments are contingent on Parent receiving proceeds and are subject to permitted deductions.
• Timing: Record date for CVR distribution — July 31, 2026; expected distribution date — August 6, 2026.

Why It Matters

• The merger transaction will make Galera and Obsidian subsidiaries of Gazelle Parent, representing a strategic ownership change that will affect Galera common shareholders and corporate control once the Mergers close.
• The $350M PIPE strengthens Galera’s financing position ahead of the closing, providing material capital via privately issued convertible preferred stock.
• The CVR distribution preserves a potential cash recovery path for Galera common shareholders tied to future dispositions or licenses of specific assets (tilarganine, GC4711, GC4419), but payments are contingent and depend on future transactions by the Parent.